|
Premier Research, the international pharmaceutical services group, announces the appointment of Patrick Melvin as Senior Director, Clinical Trial Management specializing in oncology-related research. In this position, Mr. Melvin will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology business.
Over the past nine years, Mr. Melvin managed hematology/oncology programs ranging from Phase I first-in-man studies through pivotal global Phase III programs. His early phase experience included multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, Simon two-stage studies, and adaptive design studies. The later phase studies included extensive global experience in hematology/oncology clinical research including clinical program and client activities in the United States, Western and Eastern Europe, Latin America, and Asia. His responsibilities incorporated consulting with clients on clinical development plans and protocol design for new hematology/oncology studies. Mr. Melvin began his clinical research career as a CRA at a global clinical research organization and, after five years of serving in various monitoring positions, entered project management specializing in hematology and oncology drug development.
“Mr. Melvin is an exceptional addition to our team,” said Krista Armstrong, Ph.D., Vice President, Clinical Trial Management. “As we continue to expand our presence within the oncology market, Mr. Melvin’s substantial clinical and management expertise will be beneficial in continuing to establish Premier Research as an industry leader.” |
|